Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.

Abstract

T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis. We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy. Two months after treatment, the patient showed near complete remission of the lymphadenopathy. These data suggest a possible synergistic effect with bortezomib in combination with doxorubincin and dexamethasone. To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.

• Authors: Wenyuan Mai, Haitao Meng, Jie Jin, Lei Wang
• Journal: European journal of haematology (Eur J Haematol) Vol. 77 Issue 5 Pg. 445-7 (Nov 2006) ISSN: 0902-4441 [Print] England
• PMID: 16930138 (Publication Type: Case Reports, Journal Article)

Chemical References

• Boronic Acids
• Pyrazines
• Bortezomib
• Dexamethasone
• Doxorubicin

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Boronic Acids (administration & dosage)
• Bortezomib
• Dexamethasone (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Synergism
• Humans
• Lymphoma, T-Cell (diagnostic imaging, drug therapy, pathology)
• Male
• Pyrazines (administration & dosage)
• Radiography
• Remission Induction